8
6
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4496 |
LM22B-10
LM22B10 |
ERK; Trk receptor; Akt | Cytoskeletal Signaling; MAPK; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
LM22B-10 是TrkB/TrkC 神经营养因子受体激活剂,诱导体内外TrkB、TrkC、AKT 和ERK 的活化。 | |||
T19649 |
PF-06273340
PF 6273340,PF 06273340,PF6273340,PF-6273340 |
Trk receptor | Tyrosine Kinase/Adaptors |
PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。 | |||
T5995 |
Larotrectinib
LOXO-101,ARRY-470 |
Apoptosis; Trk receptor | Apoptosis; Tyrosine Kinase/Adaptors |
Larotrectinib (LOXO-101)为ATP竞争性、口服选择性抑制剂,针对原肌凝蛋白相关激酶(TRK)家族受体三个亚型(TRKA,B 和C)展现纳摩尔级别的50%抑制浓度。 | |||
T2617 |
SNS-314 Mesylate
SNS-314 |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
SNS-314 Mesylate (SNS-314) 是一种有效且特异性的极光激酶抑制剂,对极光激酶 A、B、C 的 IC50值分别为 9,31 和 3 nM。 | |||
T14363 |
AZ-23
AZ 23,AZ23 |
Trk receptor | Tyrosine Kinase/Adaptors |
AZ-23是一种 ATP-竞争性的,口服具有活性的 Trk 激酶 A/B/C 抑制剂,IC50值分别为2 nM (TrkA),8 nM (TrkB),24 nM (FGFR1),52 nM (Flt3),55 nM (Ret),84 nM (MuSk),99 nM (Lck)。 | |||
T4071 |
Repotrectinib
TPX-0005,TPX 0005,TPX0005 |
Trk receptor; ROS; Src; ALK; ROS Kinase | Angiogenesis; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Repotrectinib (TPX-0005) 是ROS1(IC50=0.07 nM) 和TRK(对 TRKA/B/C 的IC50=0.83/0.05/0.1 nM) 抑制剂,能够抑制 WTALK(IC50=1.01 nM)。它具有抗癌作用。 | |||
T28369 |
PF-06278121
PF6278121,PF 6278121,PF-6278121 |
||
PF-06278121 is a potent and selective Trk inhibitor. PF-06278121 shows Trk A/B IC50 = 4/94 nM (enzymatic assay), Trk A/B/C IC50 = 13/7/6 nM (PathHunter cell assay). | |||
T73033 | TRK II-IN-1 | Trk receptor | Tyrosine Kinase/Adaptors |
TRKII-IN-1 是一种有效的 II 型TRK抑制剂,对TRKA/B/C及TRKAG667C的IC50分别为3.3、6.4、4.3 和 9.4 nM。此外,TRKII-IN-1 对FLT3、RET和VEGFR2也具有抑制作用,其IC50分别为1.3、9.9 和 71.1 nM。TRKII-IN-1 主要用于TRK驱动的癌症研究。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-02231 |
TrkB Protein, Mouse, Recombinant (His)
trk-B,neurotrophic tyrosine kinase, recept... |
Mouse | HEK293 Cells |
TrkB Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 46 kDa and the accession number is P15209-2. | |||
TMPY-00751 |
TrkB Protein, Human, Recombinant (His)
trk-B,GP145-TrkB/GP95- |
Human | HEK293 Cells |
TrkB Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 45.7 kDa and the accession number is Q16620-2. | |||
TMPY-05509 |
TrkB Protein, Human, Recombinant (hFc)
GP145-TrkB/GP95-TrkB, |
Human | HEK293 Cells |
TrkB Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 70.9 kDa and the accession number is Q16620-2. | |||
TMPK-01413 |
H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi)
H-2K,OVA,MHC,H2-K1 |
Mouse | HEK293 Cells |
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of the frst OVA epitopes to be characterised, it has an amino acid sequence SIINFEKL, which is recognised by cytotoxic T lymphocytes. SIINFEKL forms fbrillar assemblies similar to other peptide hydrogels. Te immunoactive properties of this peptide can therefore be related to its se... | |||
TMPK-01416 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,SARS-CoV-2 epitope |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. | |||
TMPK-01412 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi)
SARS-CoV-2 epitope,MHC |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. |